November is American Diabetes Month, and as we do our part to bring awareness to diabetes, we are also celebrating over a century of medical advancements that have transformed diabetes care. From the discovery of insulin in 1921 to today’s long and rapid-acting insulins and the new GLP-1 receptor agonists and SGLT2 inhibitors for type 2 diabetes, innovation has continually improved the health and quality of life for those living with diabetes. These innovations allow for more precise, personalized management and significantly reduce the risk of complications associated with the disease.
American Diabetes Month highlights not only the progress made, but also the ongoing need for more research to improve treatments and, ultimately, find a cure. By recognizing these advancements, we at PhRMA honor both the science and the resilience of millions affected by diabetes and we remain committed to working with policymakers to ensure Americans have affordable access to these advancements.
Drew Voytal
Drew Voytal, MPA is a Senior Director of public affairs at PhRMA focusing on advocacy and policy communications on key issues, including 340B. His career in health care advocacy, policy and public affairs spans more than a decade in Washington, DC where he has built relationships with key government and industry partners to advance public policy priorities. Drew has personally experienced the benefits of biopharmaceutical research and innovation and is passionate about telling the story of this vital industry.
Drew Voytal
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
Did the administration consider the value of innovative diabetes medicines in price setting process?
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid
4 key facts on medicine prices and spending
Insulin and reconciliation
3 factors impacting medication adherence for patients with diabetes
New insulin report highlights how incentives benefit middlemen, harm patients
Sharing rebates can improve access to medicines and increase health equity
Guest post: H.R.3 is the wrong approach to help patients like me
Guest post: Sharing discounts and rebates is the right thing to do
New report shows more than 160 medicines in development for diabetes and related conditions
Five key facts about the market for insulins
Six key facts about the market for insulins
Ask About Adherence: New study finds one-third of newly diagnosed diabetic patients aren’t starting treatment
Reality check: Value-based contracts are good for patients
Ask About Adherence: Private-sector collaboration can lead to savings and care improvement
New report shows better diabetes management saves money and improves patient outcomes
Protect your health: Important disaster preparedness tips for Harvey and Irma
mother and son happily hugging
Diabetes
Celebrating advances in diabetes research
mother and son happily hugging